Needham analyst Quinn Bolton downgrades Analog Devices (NASDAQ:ADI) from Buy to Hold.
PolyPid Announces Peer-Reviewed Publication Of Phase 2 Clinical Trial Results For D-PLEX₁₀₀ In The Prevention Of Surgical Site Infections In Abdominal Surgery
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the peer-reviewed publication of positive clinical
